Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBITDA: 2020-2025

Historic EBITDA for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.4 million.

  • Fulcrum Therapeutics' EBITDA rose 7.23% to -$19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.6 million, marking a year-over-year decrease of 195.25%. This contributed to the annual value of -$9.5 million for FY2024, which is 90.22% up from last year.
  • Fulcrum Therapeutics' EBITDA amounted to -$19.4 million in Q3 2025, which was up 4.74% from -$20.4 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' EBITDA registered a high of $52.5 million during Q2 2024, and its lowest value of -$34.0 million during Q2 2022.
  • For the 3-year period, Fulcrum Therapeutics' EBITDA averaged around -$16.6 million, with its median value being -$24.1 million (2023).
  • As far as peak fluctuations go, Fulcrum Therapeutics' EBITDA surged by 292.33% in 2024, and later plummeted by 138.87% in 2025.
  • Over the past 5 years, Fulcrum Therapeutics' EBITDA (Quarterly) stood at -$23.8 million in 2021, then dropped by 17.56% to -$28.0 million in 2022, then declined by 0.07% to -$28.0 million in 2023, then soared by 39.92% to -$16.8 million in 2024, then increased by 7.23% to -$19.4 million in 2025.
  • Its EBITDA stands at -$19.4 million for Q3 2025, versus -$20.4 million for Q2 2025 and -$16.8 million for Q4 2024.